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Results

Background

Tables

- Transcarotid artery revascularization (TCAR) is
a novel procedure to intervene on clinically
significant carotid artery stenosis1, which
involves a reversal of flow from the carotid
artery to the femoral vein
- In clinical trials the periprocedural rate of
stroke has proved exceedingly low (<1.5%)1
- Diabetic patients are known to have elevated
risk of periprocedural adverse events with
traditional carotid endarterectomy and stenting2
- Outcomes among diabetics undergoing TCAR
remain unclear
-Our aim was to determine the periprocedural
cardiovascular and cerebrovascular events
(MACCE) among patients undergoing TCAR in a
large national database

Table 1: Baseline characteristics of patients

Methods
- The Vascular Quality Initiative database was
queried for all Transcarotid Artery
Revascularization procedures from January 2012
to March 2021
- TCAR was defined by procedures involving
reversal of flow
- Baseline demographic information and
periprocedural outcomes were obtained
- In cases in which multiple procedures were
performed, only the most recent was included in
the final analysis
-Outcomes examined included stroke, TIA, MI,
death and various composite outcomes

Total

TCAR Diabetics

TCAR Non-Diabetics

19342 (100.0)

7427 (38.4)

11914 (61.6)

Male

12324 (63.7)

4737 (63.8)

7587 (63.7)

0.89

Age

74 (IQR 67-80)

73 (IQR 67-79)

75 (IQR 68-80)

<0.01

RACE

P-value

<0.01

White

17455 (90.3)

6516 (87.7)

10939 (91.8)

African American

942 (4.9)

460 (6.2)

482 (4.1)

Asian

178 (0.9)

80 (1.1)

98 (0.8)

American Indian/Alaskan
Native

79 (0.4)

41 (0.6)

38 (0.3)

Hispanic Ethnicity

774 (4)

429 (5.8)

345 (2.9)

<.001

CAD

4974 (25.7)

2125 (28.6)

2849 (23.9)

<.001

CHF

3291 (16.9)

1698 (22.9)

1593 (13.3)

<.001

HTN

17611 (91.1)

7075 (95.3)

10536 (88.5)

<.001

COPD

4944 (25.6)

1953 (26.2)

2991 (25.1)

.065

Prior PCI

5310 (27.9)

2497 (33.6)

2813 (23.6)

<.001

Prior CABG

4140 (21.4)

1989 (33.6)

2813 (23.6)

<.001

Prior Smoker

9866 (51.1)

3879 (52.2)

5987 (50.1)

<.001

Prior CEA/CAS

5373 (27.8)

2104 (28.3)

3269 (27.4)

.179

Table 2: Analysis of in-hospital outcomes between diabetic
and non-diabetic TCAR patients
TOTAL
19,341
(100.0)

TCAR
diabetics
7,427 (38.4)

TCAR
non-diabetics
11,914 (61.6)

OR (95% CI)

Death

80 (0.4)

38 (0.5)

42 (0.4)

1.45 (0.94-2.26)

.096

Stroke

272 (1.4)

123 (1.7)

149 (1.3)

1.32 (1.05-1.69)

.020

TIA

104 (0.5)

51 (0.7)

53 (0.4)

1.55 (1.05-2.28)

.027

Myocardial
infarction

106 (0.6)

50 (0.7)

56 (0.5)

1.44 (0.98-2.10)

.064

TIA or stroke

375 (1.9)

174 (2.3)

201 (1.7)

1.40 (1.14-1.72)

.001

Stroke or death

322 (1.7)

146 (2)

176 (1.5)

1.34 (1.07-1.67)

.010

Stroke or myocardial
infarction or death

P-value

- A total of 19,341 patients underwent TCAR, of
these 7427 (38.4%) were diabetics
-The risk of periprocedural stroke (OR 1.32,
p=.020), TIA (OR 1.55, p=.027), TIA/Stroke
(OR 1.40, p<.01) all suggested diabetics remain
at higher risk compared to non-diabetics
-The risk of myocardial infarction was not
significant (0.7% vs 0.5%, p=.064)
-Death remained a rare outcome (0.5% vs
0.4%, p=.096) and was not statistically
significant between the two groups
-The combined composite outcome of
stroke/death/MI noted a higher adverse event
rate (2.5% vs 1.9%, OR 1.38, p=.001) for
diabetics as well

Conclusion
- TCAR is a safe revascularization for significant
carotid artery stenosis with an elevated risk of
periprocedural MACCE in diabetics compared to
non-diabetic patients
- Further studies are need to define optimal
patient selection for this novel and less-invasive
strategy for carotid artery disease
- Of particular interest will be if other
revascularization strategies (TFCAS & CEA) offer
a lower risk among diabetics compared to TCAR
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